{"bekendtgoerelseNoegle":{"noticeId":{"value":"78e8ed0a-005c-4d84-a79e-dd4b097a830b"},"noticeVersion":{"value":"01"},"noticePublicationNumber":{"value":"00083506-2024"}},"htmlDA":"\n\n \n
1 Køber
1.1 Køber
Officielt navn: Region Midtjylland
\n
Køberens retlige status: Regional myndighed
\n
Den ordregivende myndigheds aktiviteter: Sundhed
\n
\n
\n
2 Procedure
2.1 Procedure
Titel: Delivery of two Bioreactors
\n
Beskrivelse: The department of Immunology wish to purchase two bioractors with the following specifications:\n 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration\n of conformity to CE to indicate its conformity with health, safety, and environmental\n protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing\n capabilities to enable data collection, analysis, and process control. This may include\n connectivity to a software system for real-time monitoring and control. 3. In-Process\n Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor\n and control critical culture parameters; at least temperature, pH, dissolved oxygen.\n And preferably the option include more parameters such as (inline) nutrient sensors.\n The monitoring system must allow for real-time data access and alarms for out-of-range\n conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate\n continuous volume expandable scalability, allowing for easy scale-up or scale-out\n of the cell culture process (not based on successively using bioreactors of increasing\n size). Especially the bioreactor must allow the initiation of the cell culture process\n with a relatively small amount of starting material (e.g. such as cell isolated directly\n from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate\n a sampling port or system that allows for direct and sterile sampling of the cell\n culture without disrupting the process integrity. This feature enables the analysis\n of cell culture parameters and product quality during the culture period. 6. Expansion\n Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent\n cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance\n of quality and safety standards throughout the cell expansion process. 7. Viability\n and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize\n cell viability and purity of the resulting cellular products. This must involve features\n such as controlled cell detachment mechanisms, gentle agitation methods (preferably\n lack of headspace, provides a low-shear environment), and provisions for downstream\n processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant\n Procedures: The bioreactor must support GMP-compliant cell harvesting procedures,\n which must include the implementation of automated, closed-system cell harvesting\n techniques to maintain sterility, and product integrity. 9. Flexibility in application:\n The bioreactor must support the cultivation of multiple cell types to ensure it can\n accommodate future developments in the field. It ideally allows cultivation of both\n adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic\n stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of\n contamination and reduce cost/effort for cleaning and sterilization, cells must be\n cultured in single-use bags with minimal installation requirements.
\n
Identifikator for proceduren: 593b0e3c-ade1-4b41-97cd-dfe0ded47142
\n
Intern identifikator: 1-23-4-72-6-24
\n
Udbudsprocedure: Udbud med forhandling uden forudgående offentliggørelse
\n
2.1.1 Formål
Kontraktens art: Varer
\n
Yderligere om kontraktens art: Tjenesteydelser
\n
Primær klassificering (cpv): 33000000 Medicinsk udstyr, lægemidler og produkter til personlig pleje
\n
\n
2.1.2 Udførelsessted
Landespecifik underafdeling (NUTS): Østjylland (DK042)
\n
Land: Danmark
\n
Yderligere oplysninger: Aarhus University Hospital
\n
\n
2.1.4 Generelle oplysninger
Retsgrundlag:
\n
Direktiv 2014/24/EU
\n
\n
\n
\n
5 Delkontrakt
5.1 Teknisk ID for partiet: LOT-0000
Titel: delivery of Bioreactor
\n
Beskrivelse: The department of Immunology wish to purchase two bioractors with the following specifications:\n 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration\n of conformity to CE to indicate its conformity with health, safety, and environmental\n protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing\n capabilities to enable data collection, analysis, and process control. This may include\n connectivity to a software system for real-time monitoring and control. 3. In-Process\n Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor\n and control critical culture parameters; at least temperature, pH, dissolved oxygen.\n And preferably the option include more parameters such as (inline) nutrient sensors.\n The monitoring system must allow for real-time data access and alarms for out-of-range\n conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate\n continuous volume expandable scalability, allowing for easy scale-up or scale-out\n of the cell culture process (not based on successively using bioreactors of increasing\n size). Especially the bioreactor must allow the initiation of the cell culture process\n with a relatively small amount of starting material (e.g. such as cell isolated directly\n from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate\n a sampling port or system that allows for direct and sterile sampling of the cell\n culture without disrupting the process integrity. This feature enables the analysis\n of cell culture parameters and product quality during the culture period. 6. Expansion\n Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent\n cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance\n of quality and safety standards throughout the cell expansion process. 7. Viability\n and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize\n cell viability and purity of the resulting cellular products. This must involve features\n such as controlled cell detachment mechanisms, gentle agitation methods (preferably\n lack of headspace, provides a low-shear environment), and provisions for downstream\n processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant\n Procedures: The bioreactor must support GMP-compliant cell harvesting procedures,\n which must include the implementation of automated, closed-system cell harvesting\n techniques to maintain sterility, and product integrity. 9. Flexibility in application:\n The bioreactor must support the cultivation of multiple cell types to ensure it can\n accommodate future developments in the field. It ideally allows cultivation of both\n adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic\n stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of\n contamination and reduce cost/effort for cleaning and sterilization, cells must be\n cultured in single-use bags with minimal installation requirements.
\n
Intern identifikator: 1-23-4-72-6-24
\n
5.1.1 Formål
Kontraktens art: Varer
\n
Yderligere om kontraktens art: Tjenesteydelser
\n
Primær klassificering (cpv): 33000000 Medicinsk udstyr, lægemidler og produkter til personlig pleje
\n
\n
5.1.2 Udførelsessted
Landespecifik underafdeling (NUTS): Østjylland (DK042)
\n
Land: Danmark
\n
Yderligere oplysninger: Aarhus University Hospital
\n
\n
5.1.6 Generelle oplysninger
Indkøbsprojekt, der ikke finansieres med EU-midler
\n
Udbuddet er omfattet af aftalen om offentlige udbud (GPA): ja
\n
\n
5.1.12 Udbudsvilkår
Oplysninger om undersøgelsesfrister: Kontrakten vil ikke blive indgået før udløb af en standstill periode på 10 dage regnet\n fra dagen efter offentliggørelse af denne profylaksebekendtgørelse, jf. § 4, stk.\n 1, nr. 2 i lov om Klagenævnet for Udbud (LBK nr. 593 af 2.6.2016) – tilgængelig på\n www.retsinformation.dk. Klage indgives til Klagenævnet for Udbud: Senest samtidig\n med, at en klage indgives til Klagenævnet for Udbud, skal klageren skriftligt underrette\n Region Midtjylland om, at klage indgives til Klagenævnet for Udbud, og om klagen er\n indgivet i standstill perioden, jf. lovens § 6, stk. 4. Efter underskrift af kontrakten\n vil Region Midtjylland offentliggøre en tildelingsbekendtgørelse, hvilket vil indlede\n en klagefrist. Nærmere information om klagefristen vil følge af tildelingsbekendtgørelsen.\n Klagenævnet for Udbuds egen klagevejledning er tilgængelig på Klager over udbud (kfst.dk)
\n
\n
5.1.16 Yderligere oplysninger, mægling og gennemgang
Organisation med ansvar for klager: Klagenævnet for Udbud
\n
Organisation, der leverer yderligere oplysninger om klageprocedurerne: Konkurrence- og Forbrugerstyrelsen
\n
TED eSender: Mercell Holding ASA
\n
\n
\n
\n
6 Resultater
Værdien af alle kontrakter tildelt i denne meddelelse: 250.000 Euro
\n
Direkte tildeling:
Begrundelse for direkte tildeling: Kontrakten kan kun tildeles af en bestemt økonomisk aktør på grund af manglende konkurrence af tekniske årsager
\n
Anden begrundelse: Due to the above, the buyer intends to enter into a contract with Scinus Cell Expansion\n for the delivery of two bioreactors as the acquisition is covered by the ruled on\n tenders with negotiation without prior tender notice, jf. § 80, section 3, no. 2 of\n the Danish Public Procurement Act as the contract can only be assigned to one specific\n economic actor for technical reasons. According to the buyer's market coverage, there\n are no other players on the market who can solve the requirements described above.
\n
\n
6.1 Resultat delkontrakt-ID: LOT-0000
6.1.2 Oplysninger om vinderne
Vinder:
Officielt navn: Scinus Cell Expansion
\n
Tilbud:
\n
Tilbud – Identifikator: 1-23-4-72-6-24
\n
Identifikator for delkontrakt eller gruppe af delkontrakter: LOT-0000
\n
Underentrepriseværdien er kendt: nej
\n
Underentrepriseprocentdelen er kendt: nej
\n
Kontraktoplysninger:
Identifikator for kontrakten: 1-23-4-72-6-24
\n
Titel: Delivery of two bioreactors
\n
Kontrakten tildeles som led i en rammeaftale: nej
\n
\n
\n
\n
\n
\n
8 Organisationer
8.1 ORG-0001
Officielt navn: Region Midtjylland
\n
Registreringsnummer: 29190925
\n
Afdeling: Indkøb & Medicoteknik
\n
Postadresse: Olof Palmes Allé 15  
\n
By: Aarhus N
\n
Postnummer: 8200
\n
Land: Danmark
\n
Kontaktpunkt: Camilla de Gier
\n
E-mail: camilla.degier@stab.rm.dk
\n
Telefon: +45 61126240
\n
Internetadresse: https://www.udbud.rm.dk
\n
Køberprofil: https://eu.eu-supply.com/ctm/company/companyinformation/index/253854
\n
Denne organisations roller:
Køber
\n
\n
\n
8.1 ORG-0002
Officielt navn: Klagenævnet for Udbud
\n
Postadresse: Nævnenes Hus, Tolboden 2  
\n
By: Viborg
\n
Postnummer: 8800
\n
Land: Danmark
\n
E-mail: klfu@naevneneshus.dk
\n
Telefon: +45 72405708
\n
Denne organisations roller:
Organisation med ansvar for klager
\n
\n
\n
8.1 ORG-0003
Officielt navn: Konkurrence- og Forbrugerstyrelsen
\n
Postadresse: Carl Jacobsens Vej 35  
\n
By: Valby
\n
Postnummer: 2500
\n
Land: Danmark
\n
E-mail: kfst@kfst.dk
\n
Telefon: +45 41715000
\n
Denne organisations roller:
Organisation, der leverer yderligere oplysninger om klageprocedurerne
\n
\n
\n
8.1 ORG-0004
Officielt navn: Scinus Cell Expansion
\n
Den økonomiske operatørs størrelse: Lille virksomhed
\n
Postadresse: Prof. Bronkhorstlaan 10, bld 48  
\n
By: Bilthoven
\n
Postnummer: 3723 MB
\n
Landespecifik underafdeling (NUTS): Utrecht (NL310)
\n
Land: Nederlandene
\n
E-mail: info@scinus.com
\n
Telefon: +310850509300
\n
Denne organisations roller:
Tilbudsgiver
\n
Vinder af disse delkontrakter: LOT-0000
\n
\n
\n
8.1 ORG-0005
Officielt navn: Mercell Holding ASA
\n
Registreringsnummer: 980921565
\n
Postadresse: Askekroken 11  
\n
By: Oslo
\n
Postnummer: 0277
\n
Landespecifik underafdeling (NUTS): Oslo (NO081)
\n
Land: Norge
\n
Kontaktpunkt: eSender
\n
E-mail: publication@mercell.com
\n
Telefon: +47 21018800
\n
Fax: +47 21018801
\n
Internetadresse: http://mercell.com/
\n
Denne organisations roller:
TED eSender
\n
\n
\n
\n
11 Oplysninger om bekendtgørelsen
11.1 Oplysninger om bekendtgørelsen
Identifikator for bekendtgørelsen: 78e8ed0a-005c-4d84-a79e-dd4b097a830b - 01
\n
Formulartype: Forudgående underretning om direkte tildeling
\n
Bekendtgørelsestype: Bekendtgørelse med henblik på frivillig forudgående gennemsigtighed
\n
Afsendelsesdato for bekendtgørelsen: 07-02-2024 10:48 +00:00
\n
Dato for afsendelse af bekendtgørelse (eSender): 07-02-2024 10:48 +00:00
\n
Sprog, som denne bekendtgørelse er officielt tilgængelig på: dansk 
\n
\n
11.2 Oplysninger om offentliggørelsen
Bekendtgørelsesnummer: 00083506-2024
\n
EUT-S-nummer: 28/2024
\n
Offentliggørelsesdato: 08-02-2024
\n
\n
\n \n","htmlEN":"\n\n \n
1 Buyer
1.1 Buyer
Official name: Region Midtjylland
\n
Legal type of the buyer: Regional authority
\n
Activity of the contracting authority: Health
\n
\n
\n
2 Procedure
2.1 Procedure
Title: Delivery of two Bioreactors
\n
Description: The department of Immunology wish to purchase two bioractors with the following specifications:\n 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration\n of conformity to CE to indicate its conformity with health, safety, and environmental\n protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing\n capabilities to enable data collection, analysis, and process control. This may include\n connectivity to a software system for real-time monitoring and control. 3. In-Process\n Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor\n and control critical culture parameters; at least temperature, pH, dissolved oxygen.\n And preferably the option include more parameters such as (inline) nutrient sensors.\n The monitoring system must allow for real-time data access and alarms for out-of-range\n conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate\n continuous volume expandable scalability, allowing for easy scale-up or scale-out\n of the cell culture process (not based on successively using bioreactors of increasing\n size). Especially the bioreactor must allow the initiation of the cell culture process\n with a relatively small amount of starting material (e.g. such as cell isolated directly\n from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate\n a sampling port or system that allows for direct and sterile sampling of the cell\n culture without disrupting the process integrity. This feature enables the analysis\n of cell culture parameters and product quality during the culture period. 6. Expansion\n Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent\n cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance\n of quality and safety standards throughout the cell expansion process. 7. Viability\n and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize\n cell viability and purity of the resulting cellular products. This must involve features\n such as controlled cell detachment mechanisms, gentle agitation methods (preferably\n lack of headspace, provides a low-shear environment), and provisions for downstream\n processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant\n Procedures: The bioreactor must support GMP-compliant cell harvesting procedures,\n which must include the implementation of automated, closed-system cell harvesting\n techniques to maintain sterility, and product integrity. 9. Flexibility in application:\n The bioreactor must support the cultivation of multiple cell types to ensure it can\n accommodate future developments in the field. It ideally allows cultivation of both\n adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic\n stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of\n contamination and reduce cost/effort for cleaning and sterilization, cells must be\n cultured in single-use bags with minimal installation requirements.
\n
Procedure identifier: 593b0e3c-ade1-4b41-97cd-dfe0ded47142
\n
Internal identifier: 1-23-4-72-6-24
\n
Type of procedure: Negotiated without prior call for competition
\n
2.1.1 Purpose
Main nature of the contract: Supplies
\n
Additional nature of the contract: Services
\n
Main classification (cpv): 33000000 Medical equipments, pharmaceuticals and personal care products
\n
\n
2.1.2 Place of performance
Country subdivision (NUTS): Østjylland (DK042)
\n
Country: Denmark
\n
Additional information: Aarhus University Hospital
\n
\n
2.1.4 General information
Legal basis:
\n
Directive 2014/24/EU
\n
\n
\n
\n
5 Lot
5.1 Lot technical ID: LOT-0000
Title: delivery of Bioreactor
\n
Description: The department of Immunology wish to purchase two bioractors with the following specifications:\n 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration\n of conformity to CE to indicate its conformity with health, safety, and environmental\n protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing\n capabilities to enable data collection, analysis, and process control. This may include\n connectivity to a software system for real-time monitoring and control. 3. In-Process\n Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor\n and control critical culture parameters; at least temperature, pH, dissolved oxygen.\n And preferably the option include more parameters such as (inline) nutrient sensors.\n The monitoring system must allow for real-time data access and alarms for out-of-range\n conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate\n continuous volume expandable scalability, allowing for easy scale-up or scale-out\n of the cell culture process (not based on successively using bioreactors of increasing\n size). Especially the bioreactor must allow the initiation of the cell culture process\n with a relatively small amount of starting material (e.g. such as cell isolated directly\n from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate\n a sampling port or system that allows for direct and sterile sampling of the cell\n culture without disrupting the process integrity. This feature enables the analysis\n of cell culture parameters and product quality during the culture period. 6. Expansion\n Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent\n cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance\n of quality and safety standards throughout the cell expansion process. 7. Viability\n and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize\n cell viability and purity of the resulting cellular products. This must involve features\n such as controlled cell detachment mechanisms, gentle agitation methods (preferably\n lack of headspace, provides a low-shear environment), and provisions for downstream\n processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant\n Procedures: The bioreactor must support GMP-compliant cell harvesting procedures,\n which must include the implementation of automated, closed-system cell harvesting\n techniques to maintain sterility, and product integrity. 9. Flexibility in application:\n The bioreactor must support the cultivation of multiple cell types to ensure it can\n accommodate future developments in the field. It ideally allows cultivation of both\n adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic\n stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of\n contamination and reduce cost/effort for cleaning and sterilization, cells must be\n cultured in single-use bags with minimal installation requirements.
\n
Internal identifier: 1-23-4-72-6-24
\n
5.1.1 Purpose
Main nature of the contract: Supplies
\n
Additional nature of the contract: Services
\n
Main classification (cpv): 33000000 Medical equipments, pharmaceuticals and personal care products
\n
\n
5.1.2 Place of performance
Country subdivision (NUTS): Østjylland (DK042)
\n
Country: Denmark
\n
Additional information: Aarhus University Hospital
\n
\n
5.1.6 General information
Procurement Project not financed with EU Funds.
\n
The procurement is covered by the Government Procurement Agreement (GPA): yes
\n
\n
5.1.12 Terms of procurement
Information about review deadlines: Kontrakten vil ikke blive indgået før udløb af en standstill periode på 10 dage regnet\n fra dagen efter offentliggørelse af denne profylaksebekendtgørelse, jf. § 4, stk.\n 1, nr. 2 i lov om Klagenævnet for Udbud (LBK nr. 593 af 2.6.2016) – tilgængelig på\n www.retsinformation.dk. Klage indgives til Klagenævnet for Udbud: Senest samtidig\n med, at en klage indgives til Klagenævnet for Udbud, skal klageren skriftligt underrette\n Region Midtjylland om, at klage indgives til Klagenævnet for Udbud, og om klagen er\n indgivet i standstill perioden, jf. lovens § 6, stk. 4. Efter underskrift af kontrakten\n vil Region Midtjylland offentliggøre en tildelingsbekendtgørelse, hvilket vil indlede\n en klagefrist. Nærmere information om klagefristen vil følge af tildelingsbekendtgørelsen.\n Klagenævnet for Udbuds egen klagevejledning er tilgængelig på Klager over udbud (kfst.dk)
\n
\n
5.1.16 Further information, mediation and review
Review organisation: Klagenævnet for Udbud
\n
Organisation providing more information on the review procedures: Konkurrence- og Forbrugerstyrelsen
\n
TED eSender: Mercell Holding ASA
\n
\n
\n
\n
6 Results
Value of all contracts awarded in this notice: 250.000 Euro
\n
Direct award:
Justification for direct award: The contract can be provided only by a particular economic operator because of an absence of competition for technical reasons
\n
Other justification: Due to the above, the buyer intends to enter into a contract with Scinus Cell Expansion\n for the delivery of two bioreactors as the acquisition is covered by the ruled on\n tenders with negotiation without prior tender notice, jf. § 80, section 3, no. 2 of\n the Danish Public Procurement Act as the contract can only be assigned to one specific\n economic actor for technical reasons. According to the buyer's market coverage, there\n are no other players on the market who can solve the requirements described above.
\n
\n
6.1 Result lot ldentifier: LOT-0000
6.1.2 Information about winners
Winner:
Official name: Scinus Cell Expansion
\n
Tender:
\n
Tender identifier: 1-23-4-72-6-24
\n
Identifier of lot or group of lots: LOT-0000
\n
Subcontracting value is known: no
\n
Subcontracting percentage is known: no
\n
Contract information:
Identifier of the contract: 1-23-4-72-6-24
\n
Title: Delivery of two bioreactors
\n
The contract is awarded within a framework agreement: no
\n
\n
\n
\n
\n
\n
8 Organisations
8.1 ORG-0001
Official name: Region Midtjylland
\n
Registration number: 29190925
\n
Department: Indkøb & Medicoteknik
\n
Postal address: Olof Palmes Allé 15  
\n
Town: Aarhus N
\n
Postcode: 8200
\n
Country: Denmark
\n
Contact point: Camilla de Gier
\n
Email: camilla.degier@stab.rm.dk
\n
Telephone: +45 61126240
\n
Internet address: https://www.udbud.rm.dk
\n
Buyer profile: https://eu.eu-supply.com/ctm/company/companyinformation/index/253854
\n
Roles of this organisation:
Buyer
\n
\n
\n
8.1 ORG-0002
Official name: Klagenævnet for Udbud
\n
Postal address: Nævnenes Hus, Tolboden 2  
\n
Town: Viborg
\n
Postcode: 8800
\n
Country: Denmark
\n
Email: klfu@naevneneshus.dk
\n
Telephone: +45 72405708
\n
Roles of this organisation:
Review organisation
\n
\n
\n
8.1 ORG-0003
Official name: Konkurrence- og Forbrugerstyrelsen
\n
Postal address: Carl Jacobsens Vej 35  
\n
Town: Valby
\n
Postcode: 2500
\n
Country: Denmark
\n
Email: kfst@kfst.dk
\n
Telephone: +45 41715000
\n
Roles of this organisation:
Organisation providing more information on the review procedures
\n
\n
\n
8.1 ORG-0004
Official name: Scinus Cell Expansion
\n
Size of the economic operator: Small
\n
Postal address: Prof. Bronkhorstlaan 10, bld 48  
\n
Town: Bilthoven
\n
Postcode: 3723 MB
\n
Country subdivision (NUTS): Utrecht (NL310)
\n
Country: Netherlands
\n
Email: info@scinus.com
\n
Telephone: +310850509300
\n
Roles of this organisation:
Tenderer
\n
Winner of these lots: LOT-0000
\n
\n
\n
8.1 ORG-0005
Official name: Mercell Holding ASA
\n
Registration number: 980921565
\n
Postal address: Askekroken 11  
\n
Town: Oslo
\n
Postcode: 0277
\n
Country subdivision (NUTS): Oslo (NO081)
\n
Country: Norway
\n
Contact point: eSender
\n
Email: publication@mercell.com
\n
Telephone: +47 21018800
\n
Fax: +47 21018801
\n
Internet address: http://mercell.com/
\n
Roles of this organisation:
TED eSender
\n
\n
\n
\n
11 Notice information
11.1 Notice information
Notice identifier/version: 78e8ed0a-005c-4d84-a79e-dd4b097a830b - 01
\n
Form type: Direct award preannouncement
\n
Notice type: Voluntary ex-ante transparency notice
\n
Notice dispatch date: 07-02-2024 10:48 +00:00
\n
Notice dispatch date (eSender): 07-02-2024 10:48 +00:00
\n
Languages in which this notice is officially available: Danish 
\n
\n
11.2 Publication information
Notice publication number: 00083506-2024
\n
OJ S issue number: 28/2024
\n
Publication date: 08-02-2024
\n
\n
\n \n","opsummeringDA":{"card":{"titel":"Delivery of two Bioreactors","ordregiver":"Region Midtjylland","ordregiverId":"29190925","ordregiverIdDatavasket":"29190925","publiceringsdato":"2024-02-08Z","cpvKode":"33000000","cpvTitel":"Medicinsk udstyr, lægemidler og produkter til personlig pleje","formulartype":"Forudgående underretning om direkte tildeling","formulartypeKode":"dir-awa-pre","tidsfrister":[],"alleOrdregivere":["Region Midtjylland"],"beskrivelse":"The department of Immunology wish to purchase two bioractors with the following specifications: 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration of conformity to CE to indicate its conformity with health, safety, and environmental protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing capabilities to enable data collection, analysis, and process control. This may include connectivity to a software system for real-time monitoring and control. 3. In-Process Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor and control critical culture parameters; at least temperature, pH, dissolved oxygen. And preferably the option include more parameters such as (inline) nutrient sensors. The monitoring system must allow for real-time data access and alarms for out-of-range conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate continuous volume expandable scalability, allowing for easy scale-up or scale-out of the cell culture process (not based on successively using bioreactors of increasing size). Especially the bioreactor must allow the initiation of the cell culture process with a relatively small amount of starting material (e.g. such as cell isolated directly from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate a sampling port or system that allows for direct and sterile sampling of the cell culture without disrupting the process integrity. This feature enables the analysis of cell culture parameters and product quality during the culture period. 6. Expansion Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance of quality and safety standards throughout the cell expansion process. 7. Viability and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize cell viability and purity of the resulting cellular products. This must involve features such as controlled cell detachment mechanisms, gentle agitation methods (preferably lack of headspace, provides a low-shear environment), and provisions for downstream processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant Procedures: The bioreactor must support GMP-compliant cell harvesting procedures, which must include the implementation of automated, closed-system cell harvesting techniques to maintain sterility, and product integrity. 9. Flexibility in application: The bioreactor must support the cultivation of multiple cell types to ensure it can accommodate future developments in the field. It ideally allows cultivation of both adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of contamination and reduce cost/effort for cleaning and sterilization, cells must be cultured in single-use bags with minimal installation requirements. ","bkSubTypeKode":"25","bkSubType":"Bekendtgørelse med henblik på frivillig forudgående gennemsigtighed – det generelle direktiv","erAendring":false},"indholdsType":"HENTET_FRA_TED","sekundaereOrdregivere":[],"udforelsesstedNutsCode":["DK042"],"udforelsesstedSubLand":["Østjylland"],"udforelsesstedLand":["Danmark"],"udforelsesstedBy":[],"tilbudsfrister":[],"intressentfrister":[],"deltagelsefrister":[],"antalParts":0,"antalLots":1,"udbudsDokumenter":[]},"opsummeringEN":{"card":{"titel":"Delivery of two Bioreactors","ordregiver":"Region Midtjylland","ordregiverId":"29190925","ordregiverIdDatavasket":"29190925","publiceringsdato":"2024-02-08Z","cpvKode":"33000000","cpvTitel":"Medical equipments, pharmaceuticals and personal care products","formulartype":"Direct award preannouncement","formulartypeKode":"dir-awa-pre","tidsfrister":[],"alleOrdregivere":["Region Midtjylland"],"beskrivelse":"The department of Immunology wish to purchase two bioractors with the following specifications: 1. CE-Marking: The bioreactor must comply with EU regulations and obtain a Declaration of conformity to CE to indicate its conformity with health, safety, and environmental protection standards. 2. IT Interfacing: The bioreactor must be equipped with IT interfacing capabilities to enable data collection, analysis, and process control. This may include connectivity to a software system for real-time monitoring and control. 3. In-Process Monitoring of Culture Conditions: The bioreactor must have integrated sensors to monitor and control critical culture parameters; at least temperature, pH, dissolved oxygen. And preferably the option include more parameters such as (inline) nutrient sensors. The monitoring system must allow for real-time data access and alarms for out-of-range conditions. 4. Scalability During Culture: The design of the bioreactor must facilitate continuous volume expandable scalability, allowing for easy scale-up or scale-out of the cell culture process (not based on successively using bioreactors of increasing size). Especially the bioreactor must allow the initiation of the cell culture process with a relatively small amount of starting material (e.g. such as cell isolated directly from a biopsy). 5. Direct Sampling During Culture: The bioreactor must incorporate a sampling port or system that allows for direct and sterile sampling of the cell culture without disrupting the process integrity. This feature enables the analysis of cell culture parameters and product quality during the culture period. 6. Expansion Under GMP-Compliant Conditions: The bioreactor must enable the expansion of adherent cells under Good Manufacturing Practice (GMP) compliant conditions, ensuring the maintenance of quality and safety standards throughout the cell expansion process. 7. Viability and Purity of Resulting Cellular Products: The bioreactor must be designed to optimize cell viability and purity of the resulting cellular products. This must involve features such as controlled cell detachment mechanisms, gentle agitation methods (preferably lack of headspace, provides a low-shear environment), and provisions for downstream processing integration to maintain product quality. 8. Harvesting of Cells Using GMP-Compliant Procedures: The bioreactor must support GMP-compliant cell harvesting procedures, which must include the implementation of automated, closed-system cell harvesting techniques to maintain sterility, and product integrity. 9. Flexibility in application: The bioreactor must support the cultivation of multiple cell types to ensure it can accommodate future developments in the field. It ideally allows cultivation of both adherent cells (e.g. MSCs) and suspension cells (such as T cells and hematopoietic stem cells) as well as organoids. 10. Single-use culture bags: To minimize risk of contamination and reduce cost/effort for cleaning and sterilization, cells must be cultured in single-use bags with minimal installation requirements. ","bkSubTypeKode":"25","bkSubType":"Voluntary ex-ante transparency notice – general directive","erAendring":false},"indholdsType":"HENTET_FRA_TED","sekundaereOrdregivere":[],"udforelsesstedNutsCode":["DK042"],"udforelsesstedSubLand":["Østjylland"],"udforelsesstedLand":["Denmark"],"udforelsesstedBy":[],"tilbudsfrister":[],"intressentfrister":[],"deltagelsefrister":[],"antalParts":0,"antalLots":1,"udbudsDokumenter":[]}}